Breaking News

Scinai Immunotherapeutics Names Liat Halpert Head of Business Development & Sales

Halpert brings extensive pharmaceutical sales and marketing experience and joins Scinai following 14 years at Novartis.

Scinai Immunotherapeutics Ltd., a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, has appointed Liat Halpert as Head of Business Development and Sales.

Experience

Halpert brings extensive pharmaceutical sales and marketing experience and joins Scinai following 14 years at Novartis, most recently having served as Marketing and Commercial Excellence Lead for cell and gene therapies for Central, Southern and Eastern Europe.
 
Scinai’s broad pharmaceutical development experience, along with its end-to-end biologics drug development and GMP manufacturing facility, drove the Q3 2023 launch of Scinai Bioservices, a boutique end-to-end CDMO business unit, to assist biotech companies efficiently bring their products to market.
 
Halpert’s initial focus is to expand the business by targeting European and US-based biotech companies to support further growth of the CDMO business into a significant revenue generator for Scinai as well as a key partner for small biotechnology companies.
 
Amir Reichman, Scinai’s CEO, commented, “I am pleased to welcome Liat to Scinai. Her pharmaceutical sales, marketing, and leadership experience, in particular in Israel and Europe, align with our strategic decision to grow Scinai Bioservices CDMO into a trusted provider of drug development services, including for preclinical and clinical trials and GMP manufacturing for clinical supplies.”
 
Halpert commented, “I am thrilled to join Scinai where I’ll be leading business development and sales of our state-of-the-art end-to-end CDMO services in the global biotech arena.  I am also excited to support the partnering and business development efforts for Scinai’s NanoAb therapeutics pipeline which in my opinion shows great potential for success. I believe Scinai’s future is promising and bright, and I look forward to contributing and collaborating with the team.”
 
Halpert holds an MSc. in Nutrition Science from the Hebrew University of Jerusalem.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters